Marta Lasa

Navarre Institute of Health Research — Spain

Medicine · Health Sciences

16h-index821citations74works2.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(28), Synthesis and Biological Evaluation(16), Chronic Lymphocytic Leukemia Research(13), Amyloidosis: Diagnosis, Treatment, Outcomes(13), Quinazolinone synthesis and applications(11)

Publications74 total

Minimally invasive assessment of peripheral residual disease (PRD) during maintenance or observation in patients (Pts) with multiple myeloma (MM): An update from the GEM2017FIT clinical trial
Blood·2025
Ending the undetermined significance of monoclonal gammopathies (MGUS): First results of the nomoremgus study
Blood·2025Open Access
Absence of circulating tumor cells (CTCs) defines a subtype of multiple myeloma (MM) patients (Pts) with unique clinical and biological features
Blood·2025
Baked Milk Modulates Cow’s Milk Allergy in Children: Impact of Phenotype, Age, and Intake
The Journal of Allergy and Clinical Immunology In Practice·2025
Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment
Blood·2025· 9 citedOpen Access
Clinical Significance of Measurable Residual Disease (MRD) in Light-Chain (AL) Amyloidosis
Blood·2024· 1 cited
Expanding the Eureka Study: Integrating a Comprehensive Clinical Registry with Molecular Profiling to Advance AL Amyloidosis Research
Blood·2024Open Access
Long-Term Effects of Belantamab Mafodotin Plus Bortezomib, Lenalidomide and Dexamethasone (VRd) on T Cell Exhaustion Phenotype
Blood·2024· 1 cited
Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma
Journal of Clinical Oncology·2024· 12 cited
A <scp>CD38</scp> / <scp>CD3xCD28</scp> trispecific T‐cell engager as a potentially active agent in multiple myeloma patients relapsed and/or refractory to anti‐ <scp>CD38</scp> monoclonal antibodies
British Journal of Haematology·2024· 8 cited
825P Ultra-sensitive cfDNA analysis for minimally invasive measurable residual disease detection and profiling in multiple myeloma
Annals of Oncology·2024
P-165 Advanced circulating tumor DNA (ctDNA) Profiling: Enhancing Non-Invasive Detection and Characterization of Measurable Residual Disease (MRD) in Multiple Myeloma (MM)
Clinical Lymphoma Myeloma & Leukemia·2024
A EUropean REgistry and sample sharing networK to promote the diagnosis and management of light chain Amyloidosis: The EUREKA study PA132 (#490)
2024
Biological and Clinical Significance of Undetectable Circulating Tumor Cells (CTCs) in Patients (Pts) with Multiple Myeloma (MM)
Blood·2023· 6 cited
A CD38/CD28xCD3 Trispecific T-Cell Engager (TCE) As a Potentially Active Agent in Multiple Myeloma Patients Relapsed and/or Refractory (RRMM) to Anti-CD38 Monoclonal Antibodies (mAbs)
Blood·2023· 4 cited
Minimally Invasive Assessment of Measurable Residual Disease (MRD) in Multiple Myeloma (MM)
Blood·2023· 4 cited
Supplementary Figure 3 from The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
2023Open Access
Supplementary Figure 4 from The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
2023Open Access
Supplementary Figure 2 from The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
2023Open Access
Supplementary Figure 2 from The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Bruno Paiva(31), Jesús F. San Miguel(26), Felipe Prósper(19), Diego Alignani(17), Paula Rodríguez‐Otero(17), Noemí Puig(15), María‐Victoria Mateos(14), Aintzane Zabaleta(13), Tomáš Jelı́nek(12), Alberto Órfão(12), Joaquín Martínez‐López(12), Patricia Maiso(11), Juan José Lahuerta(11), Leire Burgos(10), Sonia Gárate(9), Albert Oriol(9), María‐Teresa Cedena(9), Felipe de Arriba(9), Valentín Cabañas(9), Carlos Cativiela(9)